Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. FIX
8. BE
9. AXP
10. NDAQ

Go back to Marker Therapeutics Reports First Quarter 2020 Operating and Financial Results

Marker Therapeutics (MRKR) Misses Q1 EPS by 3c

May 11, 2020 5:11 PM EDT

Marker Therapeutics (NASDAQ: MRKR) reported Q1 EPS of ($0.14), $0.03 worse than the analyst estimate of ($0.11).

"While we are eager to initiate our planned Phase 2 trial with our novel MultiTAA-specific T cell therapy in patients with acute myeloid leukemia (AML), we anticipate that the initiation of our trial will be delayed by the impacts the COVID-19... More